This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial

Ticker(s): MDGL

Who's the expert?

Institution: Northwestern University

  • Internal medicine physician with almost 20 years of experience who treats 20 patients with NASH
  • Clinical focus in Women's health 

Interview Goal
Discussing the standard of care and the potential of Madrigal Pharma's Resmetirom for treating NASH and the new data from the Phase 3 MAESTRO-NASH trial.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.